Russian Heart Failure Journal 2007year Effect of ultra-low dose antibody to angiotensin II A1 receptor C-terminal fragment (Cardos) on the course of chronic heart failure: Results of the first clinical trial
Effect of ultra-low dose antibody to angiotensin II A1 receptor C-terminal fragment (Cardos) on the course of chronic heart failure: Results of the first clinical trial
Petrov V. I., Ivanenko V. V., Davydova N. A., Epshtein O. I., Sergeeva S. A., Kachanova M. V., Chepurina N. G., Lopatin Yu. M.
Urgency. Optimization of therapy for CHF is one of the most important issues in cardiology. The use of drugs modulating the enhanced activity of neuro-hormonal systems underlies current treatment of patients with CHF. Search for new efficient and safe medicines for treatment of CHF is continuing. Aim. Studying the effect of a preparation of antibody to the AII AT1 receptor C-terminal fragment (Cardos) as a part of combination therapy on the clinical state, cardiovascular remodeling and exercise tolerance in patients with CHF. Material and methods. This randomized, single-blinded, placebo-controlled study included 60 patients with II–IV FC CHF, LV EF≤40%. Patients were evaluated prior to the study onset and at 6 months. Evaluation included assessment of clinical state, quality of life, morpho-functional parameters of the heart, exercise tolerance and laboratory tests. Results. Study demonstrated a beneficial effect of long-term treatment with Cardos as a part of combination therapy on the course of CHF; at 6 months of follow-up, CHF FC significantly decreased by 17.3%, LV EF increased by 24%, and the 6-min walk distance increased by 10.8%.